Latest News — Page 14

Could marstacimab reshape hemophilia care in Portugal? 📊

A new cost‑effectiveness analysis models marstacimab versus standard prophylaxis and finds it may deliver better bleed prevention and quality‑adjusted life‑years at an acceptable incremental cost, with meaningful implications for budget impact and reimbursement decisions. The results give payers, clinicians, and policymakers clearer evidence to inform market access strategies.

Read the full analysis to review the assumptions, sensitivity checks, and what this could mean for patients and the health system.

#SyenzaNews #HealthEconomics #pharmaceuticals #costeffectiveness #Economicevaluation

Can Managed Entry Agreements unlock sustainable access to ATMPs without breaking healthcare budgets? 🔬

This piece breaks down the key barriers—uncertain long-term outcomes, data gaps, and pricing complexity—and presents practical strategies like real-world evidence frameworks, risk‑sharing models, and adaptive contracts to align payers, manufacturers, and regulators.

Read the full article to explore actionable approaches for designing MEAs that balance innovation, affordability, and patient access. 💡

#SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #costeffectiveness

Could biocatalysis be the key to the first oral PCSK9 inhibitor? 🔬💊

A recent breakthrough in biocatalytic synthesis is enabling scalable, stereoselective routes to small-molecule PCSK9 inhibitors — potentially turning today’s injectable therapies into convenient, lower-cost oral medicines with better patient adherence. This could reshape cardiovascular drug development, manufacturing economics, and market access.

Read the full article to see the science, commercial implications, and next steps for bringing oral PCSK9s to patients.

#SyenzaNews #biotechnology #drugdevelopment #innovation #MarketAccess

Is your GMP manufacturing program ready for EMA scrutiny around AI? 🤖🏭

The recent EMA workshop lays out practical expectations for using AI/ML in GMP — from validation and data integrity to risk management, human oversight, and continuous monitoring to safeguard product quality.

Read the full article for key takeaways and actionable steps to align your AI initiatives with regulatory expectations.

#SyenzaNews #pharmaceuticals #regulatoryaffairs #ai #innovation

Are developers missing the mark on stakeholder engagement in advanced therapies? 🔬

The article shows how misaligned priorities between developers, clinicians, payers and patients can derail adoption of cell and gene therapies, and offers practical fixes—early payer evidence planning, cross-functional commercialization teams, scalable manufacturing strategies, and patient-centric support—to bridge the gap.

Read the full piece to learn actionable steps for aligning development and engagement to speed access and commercial success. 💡

#SyenzaNews #biotechnology #drugdevelopment #MarketAccess #innovation

Are MEA health systems ready for the cost and complexity of ATMPs? 💡

This article breaks down the key reimbursement barriers—high upfront costs, limited HTA and regulatory capacity, infrastructure and manufacturing gaps—and proposes practical solutions like outcomes-based contracts, real-world evidence generation, and regional capacity building to improve patient access.

Read the full piece for strategic recommendations for payers, manufacturers, and policymakers.

#SyenzaNews #HealthEconomics #regulatoryaffairs #MarketAccess #healthcarepolicy

Is fragmented care leaving the Netherlands’ elderly behind? 🧭

This piece breaks down how a patchwork of providers, funding streams and limited data-sharing creates gaps in continuity, workforce strain and regional inequities. It also outlines practical levers—regional care networks, stronger case management and interoperable systems—to rebuild coordination and equity.

Read the full analysis to see the policy and operational steps needed to make elderly care more integrated and sustainable.

#SyenzaNews #healthcare #HealthEconomics #healthcarepolicy #resourceallocation

Is your healthcare supply business ready for South Africa’s tightened procurement regulations?

The article unpacks recent regulatory changes affecting supplier registration, B-BBEE and local-content rules, tender adjudication transparency, and enhanced audit and contract-management obligations — highlighting compliance risks and practical opportunities to win public contracts.

📌 Read the full piece for a clear compliance checklist and actionable next steps.

#SyenzaNews #regulatoryaffairs #healthcare #governance #healthcarepolicy

Are you ready for the 2026 preferential procurement rules reshaping healthcare supply chains? 🔍

New regulations introduce local-content quotas, revised evaluation scoring, and tougher compliance checks that will affect bidding strategies, pricing and supplier partnerships across pharmaceuticals and medical devices. Suppliers must reassess sourcing, certification and market-access plans to remain competitive and compliant.

Read the full breakdown for timelines, practical next steps and negotiation tips.

#SyenzaNews #healthcare #regulatoryaffairs #MarketAccess #healthcarepolicy

Ready for South Africa’s 2026 procurement shake-up in pharma and medtech? 🇿🇦

New strategic procurement regulations will tighten transparency, prioritise local participation and raise compliance and reporting requirements—reshaping tender evaluation, pricing and market access for suppliers. Learn which parts of your commercial, regulatory and supply strategies need to change now to stay competitive.

Read the full analysis for practical steps and risk/opportunity checklists.

#SyenzaNews #pharmaceuticals #MedTech #MarketAccess #governance

Could a new targeted therapy change the game for PTEN‑deficient prostate cancer? 🔬

The FDA has endorsed TruQap for prostate cancers with PTEN loss, marking a step forward for biomarker‑driven treatment and offering clinicians a precision option backed by positive trial data. ✅

Read the full article to see the trial highlights, regulatory implications, and what this means for patients and market access.

#SyenzaNews #oncology #precisionmedicine #MarketAccess #innovation

Are EU rules helping — or holding back — innovative pharmaceutical SMEs? 🔬

This article summarizes EUCOPE’s analysis of the regulatory hurdles small biotech and pharma companies face and outlines practical recommendations to improve predictability, streamline approval pathways, and support scale-up and market access. It’s a concise guide to what changes could speed drug development and strengthen Europe’s innovation ecosystem.

Read the full piece to see the recommendations and what they mean for founders, regulators, and investors. 👇

#SyenzaNews #pharmaceuticals #regulatoryaffairs #innovation #healthcarepolicy

💡 Are cardiovascular health checks the key to unlocking better health outcomes?

Recent findings reveal that structured, risk-based cardiovascular health checks not only improve diagnosis rates for chronic conditions but also provide significant economic and societal benefits. This comprehensive analysis highlights how targeted programs can enhance early detection and reduce long-term health risks across Europe.

Dive into the full article to discover the evidence-based recommendations and the potential for real-world impact on healthcare strategies!

#SyenzaNews #HealthcareInnovation #HealthEconomics #DigitalTransformation

Is Europe ready for regulatory convergence by 2026? 🚀

Rui Santos and Ivo explore how evolving regulatory frameworks and RAPS-led initiatives are moving Europe toward greater harmonization—highlighting what this means for innovation, market access, and compliance strategies. Their article outlines practical steps life‑science and health‑tech teams can take now to stay ahead of the transition.

Read the full piece to get the timeline, risks, and actionable recommendations for your organization.

#SyenzaNews #regulatoryaffairs #HealthTech #innovation #governance

💡 Are you curious about the financial impact of the Most-Favored-Nation (MFN) drug pricing policy?

This policy could save the U.S. an estimated **$529 billion** over the next decade! By linking drug prices to those of peer nations, MFN not only promises significant savings for states and consumers but also aims to maintain innovation in the pharmaceutical sector.

Dive into the analysis and find out how these projections could reshape health economics and improve patient access to essential medications.

Read more in the full article!

#SyenzaNews #HealthEconomics #HealthcarePolicy

Could a mobile app be the difference between a missed dose and better health outcomes? 📱🌍

Sandoz’s mobile-health initiative is using digital tools and community partnerships to expand access to care, support frontline workers, and improve medication adherence in underserved areas. This piece breaks down the program’s approach, early impact, and lessons for scaling mHealth solutions.

Read the full article to see how this model could reshape community health delivery.

#SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #innovation